Abstract

FDA-funded Report on Compounded Hormones is Tainted, Analysis Shows

Author(s): Brunner Scott

Issue: May/Jun 2021 - Volume 25, Number 3

Page(s): 206-209

Download in electronic PDF format for $75
  • FDA-funded Report on Compounded Hormones is Tainted, Analysis Shows Page 1
  • FDA-funded Report on Compounded Hormones is Tainted, Analysis Shows Page 2
  • FDA-funded Report on Compounded Hormones is Tainted, Analysis Shows Page 3
  • FDA-funded Report on Compounded Hormones is Tainted, Analysis Shows Page 4

Abstract

Related Keywords

  • Alliance for Pharmacy Compounding
  • U.S. Food and Drug Administration
  • FDA
  • National Academies of Science, Engineering, and Medicine
  • NASEM report
  • compounded bioidentical hormone replacement
  • cBHT
  • BHRT
  • HRT
  • Pharmacy Compounding Foundation
  • bias
  • clinical utility
  • drug safety
  • advertising
  • promotional campaign

Related Categories

  • HRT
  • LEGAL

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
May/Jun 2021
Pg. 206-209
FDA-funded Report on Compounded Hormones is Tainted, Analysis Shows
Author(s): Brunner Scott
Jul/Aug 2020
Pg. 296-297
Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed
Author(s): Brunner Scott
Nov/Dec 2020
Pg. 444
PreScription: The NASEM cBHT Report, Part 1
Author(s): Allen Loyd V Jr
Nov/Dec 2020
Pg. 446-448
NASEM Report on Compounded Topical Pain Creams
Author(s): Allen Loyd V Jr
May/Jun 2004
Pg. 181-185
Compounding in the Pharmacy Curriculum: Beyond the Basics
Author(s): Hinkle Amanda R, Newton Gail D
Jan/Feb 2001
Pg. 52-54
Using Serum Hormone Analysis to Develop Hormone Replacement Therapy Regimens - Part 2
Author(s): Ford Gina, Garcia Lea
Mar/Apr 2017
Pg. 95-102
U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies
Author(s): Yoch Doug
Sep/Oct 2020
Pg. 356
Safety and Efficacy Studies, Pharmacy Education, and the NASEM Report on Compounded Topical Pain Creams
Author(s): Allen Loyd V Jr
May/Jun 2014
Pg. 208
The U.S. Food and Drug Administration Responds to the International Academy of Compounding Pharmacists' Outsourcing Letter
Author(s): Miller David G
Jan/Feb 2023
Pg. 22-23
The U.S. Food and Drug Administration Takes Aim at Compounded Thyroid Hormone
Author(s): Brunner Scott
Jul/Aug 2016
Pg. 351
View Sample
Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines
Author(s): Allen Loyd V Jr
Sep/Oct 2017
Pg. 356
PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs
Author(s): Allen Loyd V Jr
Jan/Feb 2021
Pg. 4
PreScription: The NASEM cBHT Report, Part 2
Author(s): Allen Loyd V Jr
Jul/Aug 2015
Pg. 303-305
U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances
Author(s): Miller David G
Nov/Dec 2015
Pg. 487-488
U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs
Author(s): Allen Loyd V Jr
Nov/Dec 2020
Pg. 466-470
Gender Bias in the Treatment of Menopausal Women: I am Hot as Hell and Not Going to Take It Anymore, Part 1
Author(s): DeRosa Angela
Sep/Oct 2015
Pg. 389-390
Nominations of Difficult to Compound Drugs to the U.S. Food and Drug Administration--Pharmacy Compounding Advisory Committee: Part 1
Author(s): Allen Loyd V Jr
Jan/Feb 2021
Pg. 14-17
Gender Bias in the Treatment of Menopausal Women: I am Hot as Hell and Not Going to Take It Anymore, Part 2
Author(s): DeRosa Angela
Mar/Apr 2014
Pg. 117-118
IACP's Continuing Support of Compounding Pharmacists: Letter to the FDA Concerning 503B Outsourcing Facilities
Author(s): Miller David G
Jul/Aug 2004
Pg. 313-319
Efficacy and Tolerability of Compounded Bioidentical Hormone Replacement Therapy
Author(s): Vigesaa Kristy A, Downhour Nathan P, Chui Michelle A, Cappellini Linda, Musil John D, McCallian Dennis J